Opportunities and Challenges of Pharmacovigilance in Cancer Treatment

doi:10.19803/j.1672-8629.2021.11.08

Abstract

Abstract: Objectiv eTo introduce domestic and foreign pharmacovigilance systems and review the research progress in pharmacovigilance in the field of cancer treatment at home and abroad. Methods A comprehensive research was conducted in CNKI and PubMed from inception to May 31, 2021. Articles about pharmacovigilance in cancer treatment were reviewed, while the number of factors that made this sphere complicated were analyzed. Current opportunities as well as challenges were outlined. Results There was an increase in the demand for pharmacovigilance, IT could help reveal the potential connections between drugs and events, and patients'participation in adverse reaction reporting could add a new dimension to information collection, all of which could accelerate personalized cancer treatment. Conclusion Pharmacovigilance research in oncology will be oriented to risk prediction and personalized management of adverse drug reactions. The establishment of a better pharmacovigilance system is conducive to the safety of patients in drug use.

Key words: pharmacovigilance, cancer treatment, adverse drug reaction

CLC Number:

R994.11R916.696

ZHANG Xiaowen, HOU Wenbin, YANG Ming, LIU Jianping. Opportunities and Challenges of Pharmacovigilance in Cancer Treatment[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1034-1038.

References

[1] WHO. Pharmacovigilance[EB/OL].(2020-01-20)[2021-06-10]. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/.
[2] Yuan L, Gao Y, Lu CF.Priliminary thinking on the establishment of pharmacovigilance system in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2020, 17(11): 749-752.
[3] International Council for Harmonisation. Medical Dictionary for Regulatory Activities [EB/OL].(2021-03-24)[2021-06-10]. https://www.meddra.org/.
[4] National Cancer Institution. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0[R/OL].(2017-11-27)[2021-06-10]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
[5] National Cancer Institution. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events(PRO-CTCAE™)[R/OL].(2021-04-12)[2021-06-10].https://healthcaredelivery.cancer.gov/pro-ctcae/.
[6] Crestan D, Trojniak MP, Francescon S, et al.Pharmacovigilance of anti-cancer medicines:opportunities and challenges[J]. Expert Opin DrugSaf, 2020, 19(7): 849-860.
[7] Liu PC, Wang JY, Chen JM, et al.Pharmacovigilance Laws in Europe and America and their implications for China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(12): 877-882.
[8] National Medical Products Administration. Announcement on the Direct Report of Adverse Reactions by the Holder of the Drug Marketing Authorization[EB/OL]. (2018-10-10)[2021-05-09].http://www.cdr-adr.org.cn/drug_1/zcfg_1/zcfg_zdyz/201810/t20181010_40432.html.
[9] Curigliano G, Cardinale D, Suter T, et al.Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2012, 23(Suppl 7): i155-i166.
[10] Singh M, Alavi A, Wong R, et al.Radiodermatitis: a review of our current understanding[J]. Am J Clin Dermatol, 2016, 17(3): 277-292.
[11] Van den Berg MH, Van Dijk M, Byrne J, et al. Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE)[J].Hum Reprod, 2021, 36(6): 1561-1573.
[12] Shah RR, Curigliano G.Safety of novel targeted therapies in oncology[J]. Drug Saf, 2019, 42(2): 157-158.
[13] Baraibar I, Melero I, Ponz-Sarvise M, et al.Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer[J]. Drug Saf, 2019, 42(2): 281-294.
[14] Liebling DB, Cordova E, Deng G, et al.Pharmacovigilance of alternative medications in the cancer setting[J]. Cancer Treat Res, 2019, 171: 37-45.
[15] National Medical Products Administration. The "weapon" of human beings against cancer-anticancer drugs [EB/OL].(2019-12-13)[2021-05-12]. https://www.nmpa.gov.cn/xxgk/kpzhsh/kpzhshyp/20191213163101824.html.
[16] Shi YK, Sun Y.Manual of Medical Oncology(临床肿瘤内科手册)[M]. Beijing: People's Medical Publishing House, 2017: 42-45.
[17] Shah RR.Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology[J]. Drug Saf, 2019, 42(2): 235-245.
[18] Tewari D, Rawat P, Singh PK.Adverse drug reactions of anticancer drugs derived from natural sources[J]. Food Chem Toxicol, 2019, 123: 522-535.
[19] Baldo P, Fornasier G, Ciolfi L, et al.Pharmacovigilance in oncology[J]. Int J Clin Pharm, 2018, 40(4): 832-841.
[20] Wolf B, Zimmermann S, Arber C, et al.Safety and tolerability of adoptive cell therapy in cancer[J]. Drug Saf, 2019, 42(2): 315-334.
[21] Smith BD, Smith GL, Hurria A, et al.Future of cancer incidence in the United States: burdens upon an aging, changing nation[J]. J Clin Oncol, 2009, 27(17): 2758-2765.
[22] Murugappan MN, King-Kallimanis BL, Reaman GH, et al. Patient reported outcomes in pediatric cancer registration trials: a u.s. food and drug administration perspective[J]. J Natl Cancer Inst, 2021(1): djab087.
[23] Shachar SS, Gallagher K, Mcguire K, et al.Multidisciplinary management of breast cancer during pregnancy[J]. Oncologist, 2017, 22(3): 324-334.
[24] Cardonick E, Iacobucci A.Use of chemotherapy during human pregnancy[J]. Lancet Oncol, 2004, 5(5): 283-291.
[25] Létinier L, Jouganous J, Benkebil M, et al.Artificial Intelligence for unstructured healthcare data: application to coding of patient reporting of adverse drug reactions[J]. Clin Pharmacol Ther, 2021, 110(2): 392-400.
[26] Lavertu A, Vora B, Giacomini KM,et al.A new era in pharma-covigilance: toward real-world data and digital monitoring[J]. Clin Pharmacol Ther, 2021, 109(5): 1197-1202.
[27] Khosla S, White R, Medina J, et al.Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?[J]. F1000Research, 2018, 7: 111.
[28] Harb H, Mroue H, Mansour A, et al.A hadoop-based platform for patient classification and disease diagnosis in healthcare applications[J]. Sensors (Basel) , 2020, 20(7): 1931.
[29] Beninger P, Murray M.Review of FDA amendments act section 921 experience in posting data-mining results from the FAERS Database[J]. Clin Ther, 2021, 43(2): 380-395.
[30] Perino J, Mottal N, Bohbot Y, et al.Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: case reports and disproportionality analyses in Vigibase[J]. Br J Clin Pharmacol, 2020, 86(5): 991-998.
[31] Patras DCE, Bondon-Guitton E, Laurent G, et al.Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacod-ynamics[J]. Br J Clin Pharmacol, 2017, 83(7): 1544-1555.
[32] Li R, Curtain C, Bereznicki L, et al.Community pharmacists' knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey[J]. Int J Clin Pharm, 2018, 40(4): 878-889.
[33] Inácio P, Cavaco A, Airaksinen M.The value of patient reporting to the pharmacovigilance system: a systematic review[J]. Br J Clin Pharmacol, 2017, 83(2): 227-246.
[34] Ni X.Construction and evaluation of self-management support module based on mobile-health for lung cancer patients[D]. Hangzhou Normal University, 2019.
[35] Rolfes L, van Hunsel F, Wilkes S, et al. Adverse drug reaction reports of patients and healthcare professionals-differences in reported information[J]. Pharmacoepidemiol Drug Saf, 2015, 24(2): 152-158.
[36] Monestime S, Page R, Jordan WM, et al.Prevalence and predictors of patients reporting adverse drug reactions to health care providers during oral targeted cancer treatment[J]. J Am Pharm Assoc (2003), 2021, 61(1): 53-59.
[37] Von Itzstein MS, Smith ML, Railey E, et al.Accessing targeted therapies: a potential roadblock to implementing precision Oncology?[J]. JCO Oncol Pract, 2021: P2000927.
[38] Biagi C, Montanaro N, Buccellato E, et al.Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region)[J]. Eur J Clin Pharmacol, 2013, 69(2): 237-244.
[39] Sessa M, di Mauro G, Mascolo A, et al. Pillars and Pitfalls of the new pharmacovigilance legislation: consequences for the identification of adverse drug reactions deriving from abuse, misuse, overdose, occupational exposure, and medication errors[J]. Front Pharmacol, 2018, 9: 611.
[40] Chua IS, Gaziel-Yablowitz M, Korach ZT, et al.Artificial intelli-gence in oncology: Path to implementation[J].Cancer Med, 2021, 10(12): 4138-4149.
[41] Drago JZ, Gönen M, Thanarajasingam G, et al.Inferences about drug safety in phase iii trials in oncology: examples from advanced prostate cancer[J]. J Natl Cancer Inst, 2021, 113(5): 553-561.
[42] Fitzner K, Oteng-Mensah F, Donley P, et al.Safety of cancer therapies: at what cost?[J]. Popul Health Manag, 2017, 20(4): 318-328.
[43] Formica D, Sultana J, Cutroneo PM, et al.The economic burden of preventable adverse drug reactions: a systematic review of observ-ational studies[J]. Expert Opin Drug Saf, 2018, 17(7): 681-695.
[44] Fitzner K, Oteng MF.Impact of cost on the safety of cancer pharmaceuticals[J]. Cancer Treat Res, 2019, 171: 1-20.